CFM
ACRV icon

Catalyst Funds Management’s Acrivon Therapeutics ACRV Stock Holding History

Catalyst Funds Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,044
Closed -$7.46K – 1148
2024
Q1 		$7.46K Buy
+1,044
New +$4.85K ﹤0.01% 929

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Funds Management's ACRV Position: Q2 2024 in Review

Catalyst Funds Management sold out of Acrivon Therapeutics (ACRV) in Q2 2024, closing a stake of 1,044 shares — an estimated $7.46K sold.

Catalyst Funds Management first reported a position in ACRV in Q1 2024 and held it in 1 quarter. The position peaked at $7.46K in Q1 2024. 55 funds tracked by Wall St. Rank hold ACRV as of Q2 2024.

  • Catalyst Funds Management reported no remaining Acrivon Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,044 Acrivon Therapeutics shares in Q2 2024, an estimated $7.46K.
  • Catalyst Funds Management first reported a position in Acrivon Therapeutics in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Acrivon Therapeutics position peaked at $7.46K in Q1 2024.
  • 55 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.